Risk for symptomatic embolism can be predicted via echocardiographic vegetation features in patients with infective endocarditis.

Cordis Angioguard RX Emboli Capture Guidewire System Filter Distal Indicated for use as a guidewire and EPS to contain and remove embolic material (thrombus/debris) while performing carotid artery ...

Cordis Angioguard RX Emboli Capture Guidewire System Filter Distal Indicated for use as a guidewire and EPS to contain and remove embolic material (thrombus/debris) while performing carotid artery ...

A risk-assessment tool incorporating NT-proBNP and high-sensitivity troponin performs better than clinical scores for ...

NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for treating joint pain, have been published in the esteemed Journal of Vascular and ...

Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific ...

On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, sparking ...

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR – Free Report) in a report issued on Tuesday morning. The brokerage issued a sell rating on the stock. Separately, Lake Street ...

As World Down Syndrome Day approaches on March 21, 2025, the Canadian Down Syndrome Society (CDSS) is launching It Was Never Okay: Forward Not Backward, a national awareness initiative calling on ...

Industry leader Fungi Perfecti, LLC - makers of Host Defense® Mushroomstm ? is redefining mushroom mycelium-powered supplements with the launch of new MycoBenefitstm. While still rooted in mushroom ...

2012年，美国FDA拒绝了Osiris的骨髓来源药物Prochymal的上市申请。其宣称的干细胞修复机制与其临床数据脱节，且缺乏可验证的效力测定方法支持。这一结论在Osiris的2012年SEC文件与美国FDA 2017年细胞治疗指南中均有迹可循。这一失败揭示了关键问题：缺乏有效的效力测定、未见明确的作用机制以及未证实MSC在体内发挥"干细胞"的分化能力。